Navigation Links
Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
Date:12/6/2007

RICHMOND, Va., Dec. 6 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, announced today that it will present at the IBC 5th Annual Global Follow-On Biologics Conference on December 11, 2007 at 09:15 AM Eastern Time.

The conference, to be held at the Hyatt Regency Hotel in Reston, Virginia, will run from Monday, December 10th through Tuesday, December 11th, and will bring together corporate, regulatory, financial, and legal experts in the field of follow-on biologics. Geoffrey Allan, Ph.D., Insmed President and CEO, will discuss Insmed's comprehensive portfolio of follow-on biologics. His presentation, entitled, "The Development of a Broad Portfolio of Follow-On Biologics: Clinical/Regulatory/Analytical and Commercial Challenges and Strategies," will also highlight Insmed's strategy for providing patients greater choice through access to these innovative follow-on biologics.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit http://www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our entrance into the follow on biologics market may be unsuccessful, our common stock could be delisted from the Nasdaq Global Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Insmed Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
5. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
6. AtriCure to Present at Roth Capital Partners 2007 New York Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. MDS to Present at Thomas Weisel Partners Healthcare Conference
9. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
10. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... The Katyl Agency, a locally ... and business owners in and around Lackawanna County, is joining Meals On Wheels ... area. , Meals on Wheels of NEPA provides hand-delivered and nutritious meals to ...
(Date:6/22/2017)... , ... June 22, 2017 , ... Branches, Inc. has ... than $245,000 in grant funding to support its programs focused on providing opportunity to ... was awarded a grant by the Foundation of $15,000 to support its , Climb ...
(Date:6/22/2017)... ... June 23, 2017 , ... Despite its pervasiveness, many ... reviews available that integrate basic science with clinical practice. Now, however, a timely review ... providing clinicians with insight into the etiology of NeuP and educating preclinical scientists on ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, a ... Nashville-based private equity firm, has invested $3.35 million in the company. , ... Claritas Capital offers the smart money, speed to market and accountability we had ...
(Date:6/20/2017)... ... 2017 , ... Hayes, Inc., a leading provider of unbiased ... 5 Questions to Ask Before Entering the Maze of Genetic Testing .” Authored ... team, the book explores the various types of the more than 65,000 commercially ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... Corp. (NASDAQ: DRIO), a leading global digital health company with mobile ... presenting at the 7th annual LD Micro Invitational on Tuesday, June ... of DarioHealth will be giving the presentation and meeting with investors. ... 7th, 2017 at the Luxe Sunset Bel Air Hotel and will ... About LD Micro LD Micro was founded ...
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology: